Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Viral infections

Zika blood test approved by FDA for screening donor blood

A blood test for detecting the Zika virus in donated blood has been approved by US regulators.

The Food and Drug Administration (FDA) gave the go ahead for the cobas Zika test, which detects Zika virus RNA, to prevent the virus “entering the US drug supply”.

It will be used to test plasma samples of whole blood and blood components from volunteer donors of, and also from, living organ donors.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said it was “the first approval of a Zika virus detection test for use with screening the nation’s blood supply”.

He added: “Today’s approval is the result of a commitment by the manufacturer to work rapidly and collaboratively with the FDA and the blood collection industry to respond to a public health crisis and ensure the safety of blood in the US and its territories.”

Zika is spread mostly by mosquitoes although it can also be contracted through blood transfusion and sexual contact.

Most people with the virus will show no symptoms, although it can cause fever, joint pain, maculopapular rash, and conjunctivitis.

But it can lead to a serious neurological disease in adults, and an infection with the Zika virus during pregnancy can cause serious birth defects.

Since August 2016, the FDA has recommended screening of donor blood products when tests became available and several states have already been using the cobas Zika test under an investigational new drug (IND) application scheme.

Results from this early use and manufacturer studies found the test had a clinical specificity of more than 99%, the FDA said.

The test is not designed or approved for diagnosing the viral infection in individuals.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Zika mosquito

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.